Tolga   Sutlu

Türkçe sürüm

Tolga Sutlu

E-mail : tolgasutlusabanciuniv.edu

Personal web page

Areas of Interest :

Immunology, Cell Therapy, Gene Therapy, Regenerative Medicine

Membership :

European Society of Gene and Cell Therapy, Swedish Society of Gene and Cell Therapy, Turkish Molecular Biology Association, Turkish Society of Immunology

Publications :

Article
Kahraman, Tamer and Güçlüer, Gözde and Şimşek, İsmail and Yağcı, Fuat Cem and Yıldırım, Muzaffer and Özen, Can and Dinç, Ayhan and Gürsel, Mayda and Ikromzoda, Lolai and Sütlü, Tolga and Gay, Stephen and Gürsel, İhsan (2017) "Circulating LL37 targets plasma extracellular vesicles to immune cells and intensifies Behçet's disease severity", Journal of Extracellular Vesicles, Vol.6 ()
Duru, Adil Doğanay and Sütlü, Tolga and Wallblom, Ann and Uttervall, Katarina and Lund, Johan and Stellan, Birgitta and Gahrton, Gösta and Nahi, Hareth and Alıcı, Evren (2015) "Deletion of chromosomal region 8p21 confers resistance to Bortezomib and is associated with upregulated Decoy trail receptor expression in patients with multiple myeloma", PLoS One, Vol.10, No.9 (SCI)
Before SU Publications:

Original Research Articles

  1. Bestas B, Moreno PM, Blomberg KE, Mohammad DK, Saleh AF, Sutlu T, Nordin JZ, Guterstam P, Gustafsson MO, Kharazi S, Piatosa B, Nordin JZ, Roberts TC, Behlke MA, Wood MJ, Gait MJ, Lundin KE, El Andaloussi S, Mansson R, Berglöf A, Wengel J and Smith CI. Splice-correcting oligonucleotides restore BTK function in X-linked agammagloblunemia model. J. Clin. Invest. 2014 Sep 2;124(9):4067-81.
  2. Sutlu T, Gilljam M, Stellan B and Alici E. Inhibition of intracellular anti-viral defense mechanisms augments lentiviral transduction of human natural killer cells: implications for gene therapy. Human Gene Therapy. 2012 Oct;23(10):1090-100.
  3. Jungebluth P, Alici E, Baiguera S, Le Blanc K, Blomberg P, Bozoky B, Crowley C, Einarsson O, Grinnemo KH, Gudbjartsson T, Le Guyader S, Henriksson G, Hermanson O, Juto JE, Leidner B, Lilja T, Liska J, Luedde T, Lundin V, Moll G, Nilsson B, Roderburg C, Strömblad S, Sutlu T, Teixeira AI, Watz E, Seifalian A and Macchiarini P. Tracheobronchial transplantation with a stem-cell-seeded bioartificial nanocomposite: a proof-of-concept study. The Lancet. 2011 Dec 10;378(9808):1997-2004.
  4. Elsheikh E, Genead R, Danielsson C, Wärdell E, Andersson A, Kjaeldgaard A, Sundström E, Sutlu T, Grinnemo KH, Sylvén C. Isolation and Characterization of the SSEA-1+ Progenitor Cells from the Human Embryonic Heart. J Cytol Histol. 2011 Sep 2:122.
  5. Sutlu T, Stellan B, Gilljam M, Quezada HC, Nahi H, Gahrton G, Alici E. Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor. Cytotherapy.  2010 Dec;12(8):1044-55.
  6. Gahrton C, Nahi H, Jansson M, Wallblom A, Alici E, Sutlu T, Samuelsson J, Gahrton G. Constitutional inv(3) in myelodysplastic syndromes. Leuk Res. 2010 Dec;34(12):1627-9.
  7. Barkholt L, Alici E, Conrad R, Sutlu T, Gilljam M, Stellan B, Christensson B, Guven H, Björkström NK, Söderdahl G, Cederlund K, Kimby E, Aschan J, Ringdén O, Ljunggren HG, Dilber MS. Safety analysis of an ex-vivo expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study. Immunotherapy. 2009 Sep;1(5):753-64.
  8. Paul E, Sutlu T, Deneberg S, Alici E, Björkstrand B, Jansson M, Lerner R, Wallblom, A, Gahrton G, Nahi H. Impact of chromosome 13 deletion and plasma cell load on long-term survival of patients with multiple myeloma undergoing autologous transplantation. Oncol Rep. 2009 Jul;22(1):137-42.
  9. Sutlu T., Alici E, Jansson M, Wallblom A, Dilber MS, Gahrton G, Nahi H. The prognostic significance of 8p21 deletion in multiple myeloma. Brit  J Haematol. 2009 Jan;144(2):266-8.
  10.  Alici E, Sutlu T, Bjorkstrand B, Gilljam M, Stellan B, Nahi H, Quezada HC, Gahrton G, Ljunggren HG, and Dilber MS. Autologous anti-tumor activity by NK cells expanded from myeloma patients using GMP-compliant components. Blood. 2008 Mar 15;111(6):3155-62.
  11.  Alici E, Konstantinidis KV, Sutlu T, Aints A, Gahrton G, Ljunggren HG, Dilber MS. Anti-myeloma activity of endogenous and adoptively transferred activated natural killer cells in experimental multiple myeloma model. Exp Hematol. 2007 Dec;35(12):1839-46.
  12. Lundberg P, El-Andaloussi S, Sutlu T, Johansson H, Langel U. Delivery of short interfering RNA using endosomolytic cell-penetrating peptides. FASEB J. 2007 Sep;21(11):2664-71.
  13. Bilecen K, Ozturk UH, Duru AD, Sutlu T, Petoukhov MV, Svergun DI, Koch MH, Sezerman UO, Cakmak I, Sayers Z. Triticum durum metallothionein. Isolation of the gene and structural characterization of the protein using solution scattering and molecular modeling. J Biol Chem. 2005 Apr 8;280 (14):13701-11.

Response Letters, Review articles and Book Chapters

  1. Sutlu T, Alici E, Gahrton G, Nahi H.  In search of the molecular consequences of 8p21 deletion in multiple myeloma: commentary on Gmidéne et al. Med Oncol. 2013 Jun;30(2):569.
  2. Sutlu T, Alici E. Ex vivo expansion of natural killer cells: a question of function. Cytotherapy. 2011 Jul;13(6):767-8.
  3. Nahi H, Sutlu T, Alici E, Gahrton G. Clinical Impact of chromosomal aberrations in multiple myeloma. J Intern Med. 2011 Feb;269(2):137-47.
  4. Georgoudaki AM, Sutlu T, Alici E. Suicide gene therapy for graft-versus-host disease. Immunotherapy. 2010 Jul;2(4):521-37.
  5. Sutlu T, Alici E. Natural killer cell-based immunotherapy in cancer: current insights and future prospects. J Intern Med. 2009 Aug;266(2):154-81.
  6. Alici E, Sutlu T, Dilber MS. Retroviral gene transfer into primary human natural killer cells. Methods Mol Biol. 2009;506:127-37.